

REFERENCES FOR DRUG DOSAGE GUIDELINES FOR INFANTS AND OLDER CHILDREN

1. Custer JW, Rau RE (eds) The Harriet Lane Handbook--18th edition. St. Louis: Mosby Year Book: 2009.
2. Koratza A.A. et al. Safety and Efficacy of Sildenafil Therapy in Children with Pulmonary Hypertension. *Int J Cardiology* (2005) 100: 267-273.
3. Hayashi AH et al Topical sucralfate: effective therapy for the management of resistant peristomal and perineal excoriation. *J Pediatr Surg* 1991 ; 26(11) : 1279-81.
4. Repchinsky C (ed) Compendium of Pharmaceuticals and Specialties (CPS)—45th Edition. Ottawa: Canadian Pharmaceutical Association; 2010.
5. Nelson JD, Bradley JS. Nelson's Pocketbook of Pediatric Antimicrobial Therapy--16th Edition. Philadelphia: Lippincott Williams & Wilkins; 2006-2007.
6. Pickering LK (ed). 2006 Red Book Report of the Committee on Infectious Diseases—27th Edition. Elk Grove Village: American Academy of Pediatrics;2006.
7. McEvoy GK (ed). American Hospital Formulary Service: Drug Information 2000. Bethesda: American Society of Hospital Pharmacists; 2006.
8. Anderson PO, Knoben JE (eds). Handbook of Clinical Drug Data--9th Edition. Stamford: Appleton & Lange; 1999.
9. Aronoff GR, Bennett WM (eds) Drug Prescribing in Renal Failure, 5th edition 2007. American College of Physicians.
10. Keady S. Update on drugs for gastro-oesophageal reflux disease. *Arch Dis Child Educ Pract Ed* 2007; 92: 114-8.
11. Gillis MC (ed). Compendium of Nonprescription Products.5th Edition. Ottawa: Canadian Pharmacists Association; 1998.
12. Choong C, Kissoon N. Vasopressin in pediatric shock and cardiac arrest. *Pediatr Crit Care Med* 2008; 9:372-9.
13. Kim SY et al. Intravenous pentamidine is effective as second line Pneumocystis pneumonia prophylaxis in pediatric oncology patients. *Pediatr Blood Cancer* 2008; 50: 779-783.
14. Vondracek P et al. Efficacy of pregabalin in neuropathic pain in paediatric oncological patients. *Eur J Paediatr Neurol* 2009; 13(4): 332-6.
15. Saul JP et al. Intravenous Amiodarone for Incessant Tachyarrhythmias in Children. A Randomized, Double-Blind, Antiarrhythmic Drug Trial. *Circulation*. 2005;112: 3470-3477
16. Druka D et al. Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. *Journal of Cystic Fibrosis* 2008;7:457-459
17. Prevention of Mother to Child Transmission of HIV. www.oaktreeclinic.bc.ca

18. Jan JE et al. Melatonin therapy of pediatric sleep disorders: recent advances, why it works, who are the candidates and how to treat. *Curr Pediatr Rev* 2007; 3: 21-224.
19. Kent DA et al (eds). *Poison Management Manual* 4th edition. B.C. Drug and Poison Information Centre, Vancouver; 1997.
20. Glorieux FH. Osteogenesis Imperfecta. *Best Pract Res Clin Rheumatol* 2008. Mar;22(1): 85-100.
21. Li, BU, Lefevre F. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome. *J. Pediatr Gastroenterol Nutr* 2008 Sep; 47(3): 379-93.
22. CATMAT malaria guidelines June 2009, volume 35S1 from the Public Health Agency of Canada www.phac-aspc.gc.ca
23. Hamida FB et al. Long-term (6 months) cross-over comparison of calcium acetate with calcium carbonate as phosphate binder. *Nephron* 1993; 63: 258-262.
24. Jongerius PH et al. Effect of botulinum toxin in the treatment of drooling: A controlled clinical trial. *Pediatrics* 2004; 114:620-7.
25. O'Brien L et al. A critical review of topical local anesthetic amethocaine (Ametop) for pediatric pain. *Pediatr Drugs* 2005; 7: 41-54.
26. Antiviral Medications for Pandemic (H1N1) 2009 Influenza: Frequently Asked Questions for Health Professionals. Published by Pharmaceutical Services Division of B.C. Ministry of Health Services. Sept 18 2009
27. American Academy of Pediatrics, Provisional Committee on Quality Improvement, Subcommittee on Acute Gastroenteritis. Practice Parameter: The Management of Acute Gastroenteritis in Young Children. *Pediatrics* 1996; 97: 424-433.
28. Hanly JG, Fitzgerald MX. Meconium ileus equivalent in older patients with cystic fibrosis. *Br Med J* 1983; 286: 1411.
29. Seiklay MG. Hypertension in children. An update on treatment strategies. *Current Opinion in Pediatrics* 2007; 19: 170-177.
30. Davies J et al. Retrospective review of the effects of rhDNAse in children with cystic fibrosis. *Pediatr Pulmonol* 1997; 23(4): 243-8.
31. Adelson PD, Bratton SL, Carney NA et al. Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents. Chapter 11. Use of hyperosmolar therapy in the management of severe pediatric traumatic brain injury. *Pediatr Crit Care Med* 2003;4:S40-44.
32. Personal communications with relevant Medical Department and Division Heads, BCCH.

33. Hassall E. Decisions in diagnosing and managing chronic gastroesophageal reflux disease in children. *J Pediatr*. 2005; 146 (3 Suppl): S3-12.
34. Dawkins TN et al. Safety of intravenous use of ketorolac in infants following cardiothoracic surgery. *Cardiol Young* 2009; 19:150-108.
35. Olivieri NF et al. Iron-chelating therapy and the treatment of thalassemia. *Blood* 1997; 89 (3): 739-761.
36. Committee on Nutrition. Aluminum Toxicity in Infants and Children. *Pediatrics* 1996; 97(3): 413-416
37. American Heart Association. Part 6. Pediatric Basic and Advanced Life Support. *Circulation* 2005. 112: III-73-III-90;
38. BCCH Algorithm for Management of Convulsive Status Epilepticus in infants and children in the Emergency Department April 2010,
39. Durkan AM et al. The use of darbepoetin in infants with chronic renal impairment. *Pediatr Nephrol* 2006; 21: 694-7.
40. Khurana S et al. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. *Liver Int* 2006; 26(8): 943-8.
41. Levy RH (ed) *Antiepileptic Drugs 5th Edition*. Lippincott Williams & Wilkins, Philadelphia. 2002.
42. Maladi P, Koren G. Pharmacogenetic insights into codeine analgesia: implications to pediatric codeine use. *Pharmacogenetics* 2008; 9(9): 1267-84.
43. Strahlendorf C. Optimizing peripheral stem cell mobilization and harvest in very small children. *J Clin Apheresis* 2005; 20: 63-64.
44. Taketomo C (ed). *Pediatric Dosage Handbook*. 15th edition. Lexi Comp Inc. Cleveland; 2008.
45. Radstake et al. Drug levels and clinical responses in adalimumab strongly correlates with functional formation of antibodies against infliximab and rheumatoid arthritis. *Ann Rheum Dis* 2009; 68: 1739-45.
46. Frymoyer A et al. Current recommended dosing of vancomycin for children with invasive methicillin-resistant *Staphylococcus aureus* infections is inadequate. *Pediatr Infect Dis J* 2009; 28: 398-402
47. Lerner G et al. Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease. *Pediatr Nephrol* 2002; 17: 933-7.
48. BCCH Algorithm for Croup in the Emergency Department Sept. 20, 2007.
49. James PJ et al. The addition of ketamine to a morphine nurse-or patient-controlled analgesia infusion (PCA/NCA) increases analgesic efficacy in children with mucositis pain. *Pediatr Anesthes* 2010; 20: 805-11.
50. Rowland AG et al. Review of the efficacy of rectal paraldehyde in the management of acute and prolonged tonic-clonic convulsions. *Arch Dis Child* 2009; 94: 720-723.

51. Waisman Y, Klein BL, Boenning DA, Young GA, Chamberlain JM et al. Prospective randomized double-blind study comparing L-epinephrine and racemic epinephrine aerosols in the treatment of laryngotracheitis (croup). *Pediatrics* 1992;89:302-6.
52. Laer S et al. Development of a safe and effective pediatric dosing regimen based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. *J Am Coll Cardiol* 2005; 46:1322-30.
53. Vander Bijl P et al. Disinhibitory reactions to benzodiazepines: A review. *J Oral Maxillofac Surg* 1991; 49: 519-523.
54. BCCH Algorithm for Emergency Management of Asthma Dec.2009
55. Walsh EP et al. Evaluation of a Staged Treatment Protocol for Rapid Automatic Junctional Tachycardia After Operation for Congenital Heart Disease. *J Am Coll Cardiol* 1997;29: 1046 –53.
56. Dahiya U & Noronha P. Drug-induced acute dystonic reactions in children: alternatives to diphenhydramine therapy. *Postgrad Med* 1984; 75:286-290.
57. Greenhill L, Kollins S, Abikoff H et al. Efficacy and Safety of Immediate-Release Methylphenidate Treatment for Preschoolers with ADHD. *J Am Acad Child Adolesc Psychiatry* 2006; 45: 1284-93.
58. Fetus and newborn committee. Canadian Paediatric Society. Routine administration of Vitamin K to newborns. *Paediatrics and Child Health* 1997;2:429-31(reaffirmed Feb/10)
59. Nutrition Committee., Canadian Pediatric Society. The use of fluoride in infants and children. Ref No N02-01. *Pediatric Child Health* 2002; 7(8): 569-72.
60. Mandapati R et al. Procainamide for rate control of post-surgical junctional tachycardia. *Pediatr Cardiol* 2000; 21:123–128.
61. Burton BK. Urea Cycle Disorders. *Clinics in Liver Disease—Volume 4, Issue 4* (Nov 2000)
62. Guidelines for the diagnosis and management of asthma. Expert panel report #3. August 2007. NIH Publication EPR-3.
<http://www.nlm.nih.gov/guidelines/asthma/asthgdln.pdf>
63. Canadian Adverse Drug Reaction newsletter. July 1996; 6(3). (Cisapride warning)
64. Cramer GW et al. The role of dornase alfa in the treatment of cystic fibrosis. *Ann Pharmacother* 1996; 30(60): 656-661.
65. Bruns L.A. et al, Should β blockers be used for the chronic treatment of pediatric patients with chronic heart failure. *Pediatric Drugs* 2002; 4(12): 771-778

66. Ito S et al. Intravenous and oral propafenone for treatment of tachycardia in infants and children: Pharmacokinetics and clinical response. *J Clin Pharmacol* 1998; 38 : 496-501.
67. Manufacturer's literature.
68. Walsh TJ et al. Pharmacokinetics, safety and tolerability of caspofungin in children and adolescents. *Antimicrob Agents Chemother* 2005; 49(11): 4536-45.
69. Chrysostomou C et al. Dexmedetomidine use in a pediatric intensive care unit: Can we use it in infants after cardiac surgery? *Pediatr Crit Care Med* 2009; 10: 654-660.
70. Tutku, S. Topical estrogen therapy in labial adhesions in children: therapeutic or prophylactic? *J Pediatr Adolescent Gynecol* 2007; 20(4): 241-44.
71. Gospe SM. Pyridoxine-dependent seizures: new genetic and biochemical clues to help with diagnosis and treatment. *Curr Opin Neurol* 2006; 19:148-153.
72. University Medical Center, Jacksonville FL. Guidelines for phosphorous supplementation in adults. *Formulary* 1998;33:263.
73. Equi A et al. Long term azithromycin in children with cystic fibrosis: a randomised, placebo controlled crossover trial. *Lancet* 2002 : 360 : 978-84.
74. Frickhofen H, et al, for the German Aplastic Anemia Study Group. Antithymocyte globulin with or without cyclosporine A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. *Blood* 2003;101:1236-1242.
75. Ettenger R et al. Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. *Pediatric Transplantation* 2005; 9: 780-7.
76. Eiland LS et al. Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients. *Ann Pharmacother* 2011; 45:582-9.
77. Lee SH et al. Minimal effective dosage of recombinant human erythropoietin in spinal surgery. *Clin Orthop* 2003; 412: 71-6.
78. Youssef N et al. Dose response of PEG 3350 for the treatment of childhood fecal impaction. *J Pediatr* 2002 ; 141 :410-4
79. Evans, D et al. Intravenous ketamine sedation for painful oncology procedures. *Pediatr Anesthesia* 2005; 15(2): 131-138.
80. Zimmermann AE et al. A review of omeprazole use in the treatment of acid-related disorders in children. *Clin Ther* 2001;23(5):660-79.
81. Chan HS et al. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: double-blind, crossover trial. *Pediatrics* 1987; 79(6): 946-52.
82. Fischer JH, Patel TV, Fischer PA. Fosphenytoin. *Clinical Pharmacokinetics and Comparative Advantages in the Acute Treatment of Seizures*. *Clin Pharmacokinet* 2003;42(1):33-58
83. Bezchlibnyk-Butler K, Virani AS (eds). *Clinical Handbook of Psychotropic Drugs for Children and Adolescents* -2nd ed. Toronto: Hogrefe and Huber; 2007.
84. Carr R et al. Long-term effectiveness outcome of melatonin therapy in children with treatment-resistant circadian rhythm sleep disorders. *J Pineal Res* 2007 ; 3 :351-59.

85. Flynn JT et al. Population pharmacokinetics of amlodipine in hypertensive children and adolescents. *J Clin Pharmacol* 2006; 46: 905-916. *amlodipine*
86. Schulte PFJ. Risk of Clozapine-Associated Agranulocytosis and Mandatory White Blood Cell Monitoring. *Ann Pharmacother* 2006; 40: 683-8.
87. World Health Organization. *Cancer Pain Relief and Palliative Care in Children*. Geneva 1998.
88. Walker J et al. Sedation using dexmedetomidine in pediatric burn patients. *J Burn Care Res* 2006; 27: 206-10
89. Thomas J et al. Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America. *CID* 2008; 46: 327-360.
90. Monagle P et al. Antithrombotic therapy in neonates and children: ACCP evidence-based clinical practice guidelines (8th edition). *Chest* 2008; 133: 887S-968S.
91. First Nations, Inuit and Metis Health Committee. Canadian Paediatric Society. Vitamin D supplementation: Recommendations for Canadian mothers and infants. *Paediatrics and Child Health* 2007;12:583-9(reaffirmed Oct 2010)
92. Carr RR et al. Azithromycin for improving pulmonary function in cystic fibrosis. *Ann Pharmacother* 2004; 38: 1520-4.
93. Pappas PG et al. Clinical practice guidelines for the management of candidiasis: 2009 Update by the Infectious Diseases Society of America. *CID* 2009; 48: 503-35.
94. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. *Br J Psychiatry*. 2009 Jan; 194(1):4-9.
95. Ketter TA, Wang PW, Chandler RA et al. Dermatology precautions and slower titration yield a low incidence of lamotrigine treatment emergent rash. *J Clin Psychiatry* 2005; 66: 642-5.
96. Bozkurt P. Use of tramadol in children. *Pediatric Anaesthesia* 2005; 15: 1041-7.
97. Nyhan WL. Treatment of the Acute Crisis in Maple Syrup Urine Disease. *Arch Pediatr Adolesc Med*. 1998;152:593-598
98. National Asthma Council Australia. *Asthma Management Handbook* 2006. Melbourne 2006.
99. Zuppa AF et al. Population pharmacokinetics of ketorolac in neonates and young infants. *Am J Ther* 2009; 16(20): 143-6
100. CMV prophylaxis and treatment regimens for kidney and kidney-pancreas transplant recipients. In: *Guidebook for the Solid Organ Transplant Programme*. British Columbia Transplant Society, March 1999.
101. Hazell P, O'Connell D, Heathcote D, Henry D. Tricyclic drugs for depression in children and adolescents. *Cochrane Database Syst Rev*. 2002;(2):CD002317.
102. Van harten J et al. Negligible sublingual absorption of nifedipine. *Lancet* 1987; Dec 12: 1363-4
103. Murphy JV et al. Deaths in young children receiving nitrazepam. *J Pediatr* 1987; 111 (1): 145-7.

104. Voskuil W et al. PEG 3350 (Transipeg) versus lactulose in the treatment of childhood functional constipation: A double blind randomized, controlled multicentre trial. *Gut* 2004; 53: 1590-4.
105. Flynn JT et al. Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension. *Pediatr Nephrol* 2000; 15: 302-316.
106. Flynn JT et al. Efficacy and safety of prolonged amlodipine treatment in hypertensive children. *Pediatr Nephrol* 2005; 20:631-635
107. Standing JF et al. Diclofenac for acute pain in children. *Cochrane Database of Systematic Reviews* 2009, Issue 4. Art. No.: CD005538. DOI: 10.1002/14651858.CD005538.pub2.
108. Rose JB et al. Oral tramadol for the treatment of pain of 7-30 days' duration in children. *Anesth Analg* 2003; 96: 78-81
109. Gordillo R et al. The Nephrotic Syndrome. *Pediatr Rev* 2009; 30:94-105.
110. Batshaw ML et al. Alternative pathway therapy for urea cycle disorders: twenty years later. *J Pediatr* 2001; 138:S46-S55.
111. Gillette P, Garson A (eds) *Clinical Pediatric Arrhythmias 2nd Ed.* Philadelphia: WB Saunders: 1999
112. Micromedex. Thomson Healthcare 2009.
113. Thayu M et al. Treatment of iron deficiency anemia in pediatric inflammatory bowel disease. *Current Treatment Options in Gastroenterology* 2005; 8:411-17.
114. Pina-Garza J et al. Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures. *Epilepsia* 2009; 50(5): 1141-1149.
115. Seeman T et al. Ramipril in the treatment of hypertension and proteinuria in children with chronic kidney diseases. *Am J Hypertens* 2004. 17: 415-20.
116. Fischer JH, Patel TV, Fischer PA. Fosphenytoin. *Clinical Pharmacokinetics and Comparative Advantages in the Acute Treatment of Seizures.* *Clin Pharmacokinet* 2003;42(1):33-58
117. Risch L, Huber AR et al Diagnosis and treatment of HIT in neonates and Children *Thrombosis Research* 2006; 118(1):123-135
118. Carbaglu product monograph; provided by Orphan Europe.
119. Ramamoorthy C et al. Pharmacokinetics and side effects of milrinone in infants and children after open heart surgery. *Pediatr Anesthesia* 1998; 86:283-9.
milrinone
120. Kane JM et al. Optimizing Pharmacological treatment of psychotic disorders. *Journal of Clinical Psychiatry* 2003; 64 Suppl 12; 28.
121. Burks C et al. Meperidine for the treatment of shaking chills and fever. *Arch Intern Med* 1980. 140: 483-4.
122. Baron PW et al. Comparison of outcomes with low dose anti-thymocyte globulin with basiliximab or no induction therapy in pediatric kidney transplant recipients: a retrospective study. *Pediatric Transplantation* 2008; 12: 32-39.

123. Condren et al. The Emerging Role of Hypertonic Saline in Cystic Fibrosis-Related Pulmonary Disease. *J Pediatr Pharmacol Ther* 2007; 12: 23-30.
124. Deeks ED et al. Rabbit anti-thymocyte globulin (Thymoglobuline): a review of its use in the prevention and treatment of acute allograft rejection. *Drugs* 2009; 69 (11): 1483-1512.disorders.
125. Deeg HJ et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. *Biol Blood Marrow Transplant* 2006; 12(5): 573-84.
126. Jones BA et al. Efficacy of ethanol locks in reducing central venous catheter infections in pediatric patients with intestinal failure. *J Pediatr Surg* 2010;45:1287-93.
127. Global strategy for asthma management and prevention. *Global Initiative for Asthma (GINA) 2008*. Available at www.ginasthma.org
128. Malignant Hyperthermia Association of the United states: www.mhaus.org
129. Malowany JI et al. Enoxaparin for neonatal thrombosis: a call for a higher dose for neonates. *Thrombosis Research* 2008; 122: 826-30.
130. Infectious Diseases and Immunization Committee, Canadian Paediatric Society. Prevention and therapy of bacterial infections for children with asplenia or hyposplenia. Reference No. ID 9904. Updated Dec. 2009.
131. Borowitz D et al. Concensus report on nutrition for pediatric patients with cystic fibrosis. *J Pediatr Gastroenterol Nutr* 2002; 35(3):246-59.
132. Committee on Drugs, American Academy of Pediatrics. Use of codeine-and dextromethorphan-containing cough remedies in children. *Pediatrics* 1997; 99:918-20. Reaffirmed in February 2007.
133. Health Canada releases decision on the labelling of cough and cold products for children. Health Canada Advisory 2008-184. http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2008/2008_184-eng.php
134. Griffith KS, Lewis LS, Mail S, Parise ME. Treatment of malaria in the United States: a systematic review. *JAMA*. May 23 2007; 297(20): 2264-77.
135. Bichara MD, Goldman RD. Magnesium for treatment of asthma in children. *Can Fam Phys* 2009. 55: 887-90.
136. Dunn S et al. Emergency Contraception. SOGC Clinical Practice Guidelines. *J Obstet gynaecol Can* 2003; 25 (8): 673-9
137. Vaudry W et al. Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplantation recipients. *Am J Transplant* 2009; 9: 636-43.
138. Cassidy JT, Petty RE et al (eds). *Textbook of Pediatric Rheumatology* 5th edition. Philadelphia: Elsevier Saunders: 2005.
139. Wong LS et al. Potential for methotrexate exposure through contamination during parenteral use as an immunosuppressant. *Internal Medicine Journal* 2009; 39: 379-83.
140. Monagle P et al (eds). *Andrew's Pediatric Thromboembolism and Stroke*. 3rd ed. 2006; BC Decker Inc. Hamilton

141. Barnes S et al. The Pediatric Cardiology Pharmacopoeia: 2004 Update. *Pediatr Cardiol* 2004; 25:623-646.
142. Gralla RJ et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. *J Clin Oncol* 1999; 17: 2971-94.
143. Ellerton C et al. Modifying the Yuzpe regimen of emergency contraception: a multicentre randomized controlled trial. *Obstet Gynecol* 2003; 101: 1160-7.
144. Foerster SR et al. Pediatric Heart Failure Therapy with β -Adrenoceptor Antagonists. *Pediatr Drugs* 2008; 10(2): 125-134
145. Corman SL et al. Atomoxetine: The first non-stimulant for the management of ADHD. *Am J Health Sys Pharm* 2004; 16: 2391-2399.
146. Giland LS et al. Atomoxetine for the treatment of attention deficit hyperactivity disorder. *Ann Pharmacother* 2004; 38: 86-89.
147. Haymond MW et al. Mini-dose glucagons rescue for hypoglycaemia in children with type 1 diabetes. *Diabetes Care* 2001; 24(4): 643-5.
148. Altman A (ed). *Supportive Care of Children with Cancer. Current therapy and guidelines from the Children's Oncology Group—3rd edition*. Baltimore: The Johns Hopkins University Press; 2004.
149. Chapman TM et al. Basiliximab: A review of its use as induction therapy in renal transplantation. *Drugs* 2003; 63(24): 2803-35.
150. Canadian Paediatric Society Position Statement (ID 2007-03) Therapy of suspected bacterial meningitis in Canadian children six weeks of age and older—summary. *Pediatr Child Health* 2008; 13(4).
151. Summar M. Current strategies for the management of neonatal urea cycle disorders. *J Pediatr* 2001; 138: S30-S39.
152. Crandall WV et al. Infusion reaction to infliximab in children and adolescents: frequency, outcome and predictive model. *Aliment Pharmacol Ther* 2003; 17: 75-84.
153. Munro MG et al. Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding. A randomized controlled trial. *American College of Obstetricians and Gynecologists* 2006; 108(4): 924-9. *Brevicon*
154. Wohl E et al. Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. *Kidney Int* 2004; 66: 768-76.
155. Wolbink et al. Development of antiinfliximab antibodies and relationship to clinical response inpatients with rheumatoid arthritis. *Arthritis & Rheumatism* 2006; 54(3): 711-5.
156. Kimura Y et al. Treatment of chronic pain in pediatric rheumatic disease. *Nat Clin Pract Rheumatol* 2007; 3:210-218
157. Sidhu S et al. Estrogen-based therapy for acute dysfunctional uterine bleeding. *CPJ/RPC* 2006; 139(3): 60-61
158. Sidhu J et al, "The Pharmacokinetic and Pharmacodynamic Consequences of the Co-administration of Lamotrigine and a Combined Oral Contraceptive in Healthy Female Subjects," *Br J Clin Pharmacol*, 2006, 61(2):191-9.
159. Onland W et al. Ethanol-lock technique for persistent bacteremia of long-term intravascular devices in pediatric patients. *Arch Pediatr Adolesc Med* 2006, 160:1049-53.
160. Canadian ADHD practice guidelines 2008 from the Canadian Attention Deficit hyperactivity Disorder Resource Alliance located at: www.caddra.ca

161. Nick JA. Non tuberculous mycobacteria in cystic fibrosis. *Seminars in Respiratory and Critical Care Medicine* 2003; 24(6): 693-702.
162. Riikonen R. Infantile spasms: therapy and outcome. *J Child Neurol* 2004; 19: 401-404.
163. Gore L et al. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. *Pediatr Blood Cancer* 2009; 52:242-7.
164. Williams DG et al. Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability. *Br J Anaesth* 2002; 89: 839-45.
165. Curry JI et al. Erythromycin as a prokinetic agent in infants and children. *Aliment Pharmacol Ther* 2001; 15(5); 595-603.
166. Health Canada. Canadian recommendations for the prevention and treatment of malaria among international travelers. *CCDR* 2004; 30SI:1-62
167. Marra F, Satzman JR, Ensom MHH. Atovaquone-proguanil for prophylaxis and treatment of malaria. *Ann Pharmacother* 2003; 37:1266-75.
168. www.palliatedrugs.com/glycopyrronium
169. Elbe D, Carandang CG. Focus on Ziprasidone: A Review of its use in Child and Adolescent Psychiatry. *Journal of the Canadian Academy of Child and Adolescent Psychiatry* 2008; 17: 220-9
170. Kirklin JK. Mechanical circulatory support as a bridge to pediatric cardiac transplantation. *Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu.* 2008; 80-5